肝脏中外排转运蛋白的研究展望。
A perspective on efflux transport proteins in the liver.
机构信息
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.
出版信息
Clin Pharmacol Ther. 2012 Nov;92(5):599-612. doi: 10.1038/clpt.2012.79. Epub 2012 Sep 5.
Abstract
Detailed knowledge regarding the influence of hepatic transport proteins on drug disposition has advanced at a rapid pace over the past decade. Efflux transport proteins located in the basolateral and apical (canalicular) membranes of hepatocytes play an important role in the hepatic elimination of many endogenous and exogenous compounds, including drugs and metabolites. This review focuses on the role of these efflux transporters in hepatic drug excretion. The impact of these proteins as underlying factors for disease is highlighted, and the importance of hepatic efflux proteins in the efficacy and toxicity of drugs is discussed. In addition, a brief overview of methodology to evaluate the function of hepatic efflux transport proteins is provided. Current challenges in predicting the impact of altered efflux protein function on systemic, intestinal, and hepatocyte exposure to drugs and metabolites are highlighted.
摘要
在过去的十年中，人们对肝转运蛋白对药物处置的影响的了解取得了飞速的发展。位于肝细胞基底外侧和顶膜（胆小管）的外排转运蛋白在许多内源性和外源性化合物（包括药物和代谢物）的肝消除中发挥着重要作用。这篇综述重点介绍了这些外排转运蛋白在肝药物排泄中的作用。强调了这些蛋白作为疾病基础因素的作用，并讨论了肝外排蛋白在药物疗效和毒性中的重要性。此外，还简要概述了评估肝外排转运蛋白功能的方法学。强调了预测改变外排蛋白功能对药物和代谢物全身、肠道和肝细胞暴露影响方面所面临的挑战。
相似文献
1
A perspective on efflux transport proteins in the liver.
Clin Pharmacol Ther. 2012 Nov;92(5):599-612. doi: 10.1038/clpt.2012.79. Epub 2012 Sep 5.
2
Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
J Clin Pharmacol. 2016 Jul;56 Suppl 7:S23-39. doi: 10.1002/jcph.671.
3
Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay.
Drug Metab Dispos. 2018 May;46(5):680-691. doi: 10.1124/dmd.117.079236. Epub 2018 Jan 19.
4
Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics.
Annu Rev Pharmacol Toxicol. 2014;54:509-35. doi: 10.1146/annurev-pharmtox-011613-140021. Epub 2013 Oct 23.
5
Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.
Clin Pharmacol Ther. 2013 Jul;94(1):126-41. doi: 10.1038/clpt.2013.78. Epub 2013 Apr 10.
6
Interaction of Drug or Food with Drug Transporters in Intestine and Liver.
Curr Drug Metab. 2015;16(9):753-64. doi: 10.2174/138920021609151201113537.
7
Liver transporters in hepatic drug disposition: an update.
Curr Drug Metab. 2009 Jun;10(5):482-98. doi: 10.2174/138920009788898037.
8
Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity.
Adv Exp Med Biol. 2019;1141:293-340. doi: 10.1007/978-981-13-7647-4_6.
9
Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations.
J Pharm Sci. 2017 Sep;106(9):2815-2825. doi: 10.1016/j.xphs.2017.04.056. Epub 2017 May 3.
10
Membrane transport as a determinant of the hepatic elimination of drugs and metabolites.
Clin Exp Pharmacol Physiol. 1996 Oct-Nov;23(10-11):970-4. doi: 10.1111/j.1440-1681.1996.tb01151.x.
引用本文的文献
1
Multidrug Resistance-Associated Proteins 3 and 5 Play a Role in the Hepatic Transport of Mercuric Conjugates of Glutathione.
Int J Mol Sci. 2025 Jan 30;26(3):1194. doi: 10.3390/ijms26031194.
2
Does Bisphenol A (BPA) Exposure Cause Human Diseases?
Biomedicines. 2024 Nov 25;12(12):2678. doi: 10.3390/biomedicines12122678.
3
Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches.
Int J Mol Sci. 2024 Dec 6;25(23):13121. doi: 10.3390/ijms252313121.
4
Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes.
Front Pharmacol. 2022 Sep 21;13:1004010. doi: 10.3389/fphar.2022.1004010. eCollection 2022.
5
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells.
Biopharm Drug Dispos. 2022 Dec;43(6):265-271. doi: 10.1002/bdd.2333. Epub 2022 Oct 27.
6
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.
Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44. doi: 10.1007/s00280-022-04446-y. Epub 2022 Jun 25.
7
Mouse precision-cut liver slices as an ex vivo model to study drug-induced cholestasis.
Arch Toxicol. 2022 Sep;96(9):2523-2543. doi: 10.1007/s00204-022-03321-2. Epub 2022 Jun 16.
8
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
PLoS One. 2021 Sep 23;16(9):e0257477. doi: 10.1371/journal.pone.0257477. eCollection 2021.
9
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
Mol Pharm. 2021 Aug 2;18(8):2997-3009. doi: 10.1021/acs.molpharmaceut.1c00206. Epub 2021 Jul 20.
10
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Clin Transl Sci. 2021 Jul;14(4):1431-1443. doi: 10.1111/cts.12992. Epub 2021 May 1.
本文引用的文献
1
Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway.
Hepatology. 2012 May;55(5):1485-94. doi: 10.1002/hep.24801.
2
MALDI imaging mass spectrometry: bridging biology and chemistry in drug development.
Bioanalysis. 2011 Nov;3(21):2427-41. doi: 10.4155/bio.11.232.
3
Strategies to produce hepatocytes and hepatocyte-like cells from pluripotent stem cells.
Hepatol Res. 2012 Feb;42(2):111-9. doi: 10.1111/j.1872-034X.2011.00896.x. Epub 2011 Oct 11.
4
Canalicular ABC transporters and liver disease.
J Pathol. 2012 Jan;226(2):300-15. doi: 10.1002/path.3019.
5
Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.
Br J Pharmacol. 2012 Mar;165(6):1836-1847. doi: 10.1111/j.1476-5381.2011.01672.x.
6
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.
Curr Drug Metab. 2011 Dec;12(10):932-43. doi: 10.2174/138920011798062283.
7
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Gastroenterology. 2011 Oct;141(4):1314-22, 1322.e1-5. doi: 10.1053/j.gastro.2011.06.075. Epub 2011 Jul 13.
8
Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.
Drug Metab Pharmacokinet. 2011;26(4):374-86. doi: 10.2133/dmpk.dmpk-10-rg-103. Epub 2011 Apr 22.
9
NSAID acyl glucuronides and enteropathy.
Curr Drug Metab. 2011 Mar;12(3):245-52. doi: 10.2174/138920011795101877.
10
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18.
Zotero 插件